- Home
- BWFG vs ADCT Comparison
BWFG vs ADCT Comparison
Compare BWFG & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BWFG | ADCT |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.0M | 439.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BWFG | ADCT |
|---|---|---|
| Price | $47.54 | $3.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $53.00 | $7.60 |
| AVG Volume (30 Days) | 30.5K | ★ 565.6K |
| Earning Date | 01-29-2026 | 11-10-2025 |
| Dividend Yield | ★ 1.69% | N/A |
| EPS Growth | ★ 88.52 | N/A |
| EPS | ★ 3.66 | N/A |
| Revenue | ★ $94,282,000.00 | $75,209,000.00 |
| Revenue This Year | $68.08 | $12.48 |
| Revenue Next Year | $13.72 | $5.12 |
| P/E Ratio | $12.93 | ★ N/A |
| Revenue Growth | ★ 30.93 | 6.35 |
| 52 Week Low | $26.39 | $1.05 |
| 52 Week High | $51.54 | $4.80 |
Technical Indicators
Market Signals| Indicator | BWFG | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 46.33 |
| Support Level | $46.81 | $3.48 |
| Resistance Level | $50.19 | $3.87 |
| Average True Range (ATR) | 1.40 | 0.21 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 44.81 | 37.25 |
Price Performance
Historical ComparisonAbout BWFG Bankwell Financial Group Inc.
Bankwell Financial Group Inc is a bank holding company, engaged in providing financial products and services. It offers products related to commercial lending, retail lending, depository services, and others. The bank's commercial lending products includes owner-occupied commercial real estate loans, commercial real estate investment loans, commercial loans to small and mid-sized businesses and real estate construction and development loans. The retail lending products include residential mortgage loans, home equity lines of credit, and consumer installment loans. Its depository products include checking, savings, money market, certificates of deposit, noninterest-bearing demand, and time deposits.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).